Method for self-organizing and forming vascularized heart organoid and heart organoid

Through the suspension culture of pluripotent stem cells and the continuous induction of differentiation of multiple culture media, the problem of insufficient vascularization of cardiac organoids is solved by using inducing differentiation factors such as CHIR99021, IWP2, VEGF-A and LN521, and the problem of insufficient vascularization of cardiac organoids is achieved more efficiently and more Stable vascularized cardiac organoid culture enhances the function and structure of the organ and provides a more reliable model for cardiovascular disease research.

CN119020273APending Publication Date: 2024-11-26WUHAN CHOPPER BIOLOGY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411229349.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-11-26

Smart Images

  • Figure CN119020273A_ABST
    Figure CN119020273A_ABST
Patent Text Reader

Abstract

The invention discloses a method for self-organizing and forming a vascularized heart organoid and the heart organoid, and relates to the technical field of medicines. The method comprises the following steps: S10, providing pluripotent stem cells, and carrying out suspension culture on the pluripotent stem cells to form embryoid bodies; s20, continuously culturing the embryoid by adopting a plurality of culture mediums, and performing induced differentiation to obtain a self-organized vascularized heart organ; wherein the components in the multiple culture mediums comprise LN521, and the heart organ obtained by the method disclosed by the invention not only contains myocardial cells, fibroblasts and epicardium, can beat autonomously, but also has a lumen structure formed by vascular endothelial cells formed by self-organization, so that the heart organ can be used for preparing the heart organ. The formation of the blood vessel lumen enables the structure of the heart organ to be closer to the real heart, and can be used in the fields of heart development, regenerative medicine and cardiovascular drug screening.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of medical technology, and in particular to a method for self-organizing the formation of vascularized cardiac organoids and cardiac organoids. Background Art

[0002] Vascular diseases pose a serious threat to human health, but there is currently a lack of ideal models to study their treatments. The human heart is one of the most complex organs in the human body in terms of structure and function. It is composed of many different types of cells, including a large number of cardiomyocytes, which interact with the vascular system and are surrounded by an extracellular matrix network containing various proteins and molecules that provide the nutrients and signaling molecules required by cells. Traditional cell culture and animal models lack the specific three-dimensional structure and function of the human heart or have species differences, while cardiac organoids can better simulate the tissue structure, function and complex microenvironment of the heart, and can therefore be used for drug screening, disease simulation, regenerative medicine, and combined with gene editing for the study of embryonic developmental biology.

[0003] In recent years, the research on cardiac organoids has shown great potential in the fields of regenerative medicine and drug screening. There are currently a variety of methods for constructing vascularized cardiac organoids. However, the degree of vascularization of organoids cultivated by existing technologies is limited, which affects their long-term survival and functional performance. For example, stem cells are used to induce the production of endocardial cells or human umbilical vein endothelial cells (HUVEC), or stem cells are used to induce vascular organoids and co-culture them with cardiac organoids for vascularization of cardiac organoids. However, the cardiac organoids constructed by these construction methods cannot form vascular lumens, and the vascular maturity and morphological structure are poor. Subsequent research on heart disease and drug response is not accurate enough. Therefore, it is necessary to continue to discover a new construction method that can achieve more efficient and stable organoid culture, and provide a more reliable experimental model and potential treatment strategy for the treatment of heart disease. Summary of the invention

[0004] The main purpose of this application is to propose a method for self-organizing to form vascularized cardiac organoids and cardiac organoids, aiming to solve the problem that vascular lumens cannot be formed in cardiac organoids, and to provide a cardiac organoid that can self-organize and differentiate to form vascular lumens, a microenvironment that is closer to physiological conditions, and can achieve more efficient and stable organoid culture, which can be better used in the study of cardiovascular diseases.

[0005] In some embodiments, the present application provides a method for self-organizing to form a vascularized cardiac organoid, comprising the following steps:

[0006] S10, providing pluripotent stem cells, and culturing the pluripotent stem cells in suspension to form embryoid bodies;

[0007] S20, continuously culturing the embryoid bodies using a variety of culture media to induce differentiation, thereby obtaining self-tissues to form vascularized cardiac organoids;

[0008] Among them, the components in the multiple culture media include LN521.

[0009] In some embodiments, the pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells.

[0010] In some embodiments, the steps of step S10 include:

[0011] Step 101, providing pluripotent stem cells, mixing the pluripotent stem cell suspension with a cell suspension, incubating overnight, changing the medium, and culturing at 35-37° C. for 24 h to 48 h to form embryoids.

[0012] In some embodiments, in step S20, any of the multiple culture media includes a basal culture medium and a differentiation inducing factor, and the multiple culture media include a first culture medium, a second culture medium, a third culture medium, a fourth culture medium, and a fifth culture medium, wherein:

[0013] The differentiation inducing factors of the first culture medium include CHI R99021 and sodium tanshinone; and / or,

[0014] The differentiation inducing factors of the second culture medium include IWP2, IWP4 and SB431542; and / or,

[0015] The differentiation inducing factors of the third culture medium include IWP2, VEGF-A and LN-521; and / or,

[0016] The differentiation inducing factors of the fourth culture medium include insulin, VEGF-A and LN-521; and / or,

[0017] The differentiation inducing factors of the fifth culture medium include insulin and VEGF-A.

[0018] In some embodiments, wherein the basal medium of the first culture medium comprises 1640 and B27 without insulin; and / or,

[0019] The basal medium of the second culture medium comprises 1640 and B27 without insulin; and / or,

[0020] The basal medium of the third culture medium comprises 1640 and B27 without insulin; and / or,

[0021] The basal medium of the fourth culture medium comprises 1640 and B27 without insulin; and / or,

[0022] The basal medium of the fifth culture medium includes DMEM and palmitic acid.

[0023] In some embodiments, in step S20,

[0024] The differentiation inducing factors of the first culture medium include CHI R99021 and sodium tanshinone, wherein the concentration of CHI R99021 is 3-10 μM, and the concentration of sodium tanshinone is 5-10 ng / mL; and / or,

[0025] The differentiation inducing factors of the second culture medium include IWP2, IWP4 and SB431542, wherein the concentration of IWP2 is 1.25-5 μM, the concentration of IWP4 is 1.25-5 μM, and the concentration of LN-521 is 10-200 ng / mL; and / or,

[0026] The differentiation inducing factors of the third culture medium include IWP2, VEGF-A and LN-521, wherein the concentration of IWP2 is 1.25-5 μM, the concentration of VEGF-A is 5-10 ng / mL and the concentration of LN-521 is 10-200 ng / mL; and / or,

[0027] The differentiation inducing factors of the fourth culture medium include insulin, VEGF-A and LN-521, wherein the concentration of insulin is 5-10 μg / mL, the concentration of VEGF-A is 5-10 ng / mL and the concentration of LN-521 is 10-200 ng / mL; and / or,

[0028] The differentiation inducing factors of the fifth culture medium include insulin and VEGF-A, wherein the concentration of the insulin is 5 to 10 μg / mL and the concentration of the VEGF-A is 5 to 10 ng / mL.

[0029] In some embodiments, the basal medium of the fifth culture medium includes DMEM and palmitic acid, and the concentration of the palmitic acid is 20 to 50 μM.

[0030] The present application also provides a cardiac organoid, wherein the cardiac organoid is prepared by the method for self-organization to form a vascularized cardiac organoid as described in any one of the above.

[0031] In the technical solution of the present application, continuous culture is carried out using multiple culture media, wherein the components in the multiple culture media include LN521, and differentiation is induced by multiple culture media, so that the growing cardiac organoids include a tubular structure and a chamber structure similar to that of the heart, which can simulate the nutrient supply and metabolite discharge of cardiac tissue, so that the cardiac organoids grow larger, the heart can beat obviously, and have a greater cardiac contractility, which is better used for the study of cardiovascular diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 A schematic diagram of the induction process for preparing the cardiac organoids of Example 1;

[0033] Figure 2 These are bright field photos of Example 1 and Comparative Example 1 on the 10th day of induction differentiation;

[0034] Figure 3 CD31+ immunofluorescence staining images of regions with vascular cavities in Example 1 and Comparative Example 1;

[0035] Figure 4 The bar graphs are CD31+ area, annular blood vessel area and annular blood vessel area / CD31+ area (%) of the region with vascular cavity in Example 1 and Comparative Example 1;

[0036] Figure 5 This is the whole-body immunofluorescence staining image of the cardiac organoid in Example 1;

[0037] Figure 6 The diagrams are the analysis of the cardiomyocyte structure and the detection of lactate dehydrogenase (LDH) activity in the cardiac organoids in Example 1 and Comparative Example 1;

[0038] Figure 7 Statistical graphs of cardiac contraction and beating frequency of cardiac organoids in Example 1 and Comparative Example 1;

[0039] Figure 8 Schematic diagram of the fluorescence changes of calcium signals in cardiac organoids in Example 1 and Comparative Example 1. DETAILED DESCRIPTION

[0040] Hereinafter, the battery separator and its preparation method, secondary battery and electrical device of the present application are specifically disclosed in detail with appropriate reference to the accompanying drawings. However, there may be cases where unnecessary detailed descriptions are omitted. For example, there are cases where detailed descriptions of well-known matters and repeated descriptions of actually the same structure are omitted. This is to avoid the following description from becoming unnecessarily lengthy and to facilitate the understanding of those skilled in the art. In addition, the drawings and the following descriptions are provided for those skilled in the art to fully understand the present application and are not intended to limit the subject matter described in the claims.

[0041] The "range" disclosed in the present application is defined in the form of a lower limit and an upper limit, and a given range is defined by selecting a lower limit and an upper limit, and the selected lower limit and upper limit define the boundaries of the particular range. The range defined in this way can be inclusive or exclusive of the end values, and can be arbitrarily combined, that is, any lower limit can be combined with any upper limit to form a range. For example, if a range of 60 to 120 and 80 to 110 is listed for a particular parameter, it is understood that a range of 60 to 110 and 80 to 120 is also expected. In addition, if the minimum range values ​​1 and 2 are listed, and if the maximum range values ​​3, 4 and 5 are listed, the following ranges can all be expected: 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4 and 2 to 5. In the present application, unless otherwise specified, the numerical range "a to b" represents an abbreviation of any real number combination between a and b, where a and b are both real numbers. For example, the numerical range "0-5" means that all real numbers between "0-5" are listed in this document, and "0-5" is just an abbreviation of these numerical combinations. In addition, when a parameter is expressed as an integer ≥ 2, it is equivalent to disclosing that the parameter is, for example, an integer of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, etc.

[0042] Unless otherwise specified, all embodiments and optional embodiments of the present application can be combined with each other to form a new technical solution.

[0043] Unless otherwise specified, all technical features and optional technical features of this application can be combined with each other to form a new technical solution.

[0044] If there is no special explanation, all steps of the present application can be performed sequentially or randomly, preferably sequentially. For example, the method includes steps (a) and (b), which means that the method may include steps (a) and (b) performed sequentially, or may include steps (b) and (a) performed sequentially. For example, the method may further include step (c), which means that step (c) may be added to the method in any order. For example, the method may include steps (a), (b) and (c), or may include steps (a), (c) and (b), or may include steps (c), (a) and (b), etc.

[0045] If there is no special explanation, the "include" and "comprising" mentioned in this application represent open-ended or closed-ended expressions. For example, the "include" and "comprising" may represent that other components not listed may also be included or only the listed components may be included or only the listed components may be included.

[0046] If not specifically stated, in this application, the term "or" is inclusive. For example, the phrase "A or B" means "A, B, or both A and B". More specifically, any of the following conditions satisfies the condition "A or B": A is true (or exists) and B is false (or does not exist); A is false (or does not exist) and B is true (or exists); or both A and B are true (or exist).

[0047] In recent years, the research on cardiac organoids has shown great potential in the fields of regenerative medicine and drug screening. There are currently a variety of methods for constructing vascularized cardiac organoids. However, the degree of vascularization of organoids cultivated by existing technologies is limited, which affects their long-term survival and functional performance. For example, stem cells are used to induce the production of endocardial cells or human umbilical vein endothelial cells (HUVEC), or stem cells are used to induce vascular organoids and co-culture them with cardiac organoids for vascularization of cardiac organoids. However, the cardiac organoids constructed by these construction methods cannot form vascular lumens, so the vascular maturity and morphological structure are poor, and subsequent research on heart disease and drug response is not accurate enough. Therefore, it is necessary to continue to discover a new construction method that can achieve more efficient and stable organoid culture, providing a more reliable experimental model and potential treatment strategy for the treatment of heart disease.

[0048] In view of this, the present application provides a method for self-organizing to form vascularized cardiac organoids, comprising the following steps:

[0049] S10, providing pluripotent stem cells, and culturing the pluripotent stem cells in suspension to form embryoid bodies;

[0050] S20, continuously culturing the embryoid bodies using a variety of culture media to induce differentiation, thereby obtaining self-tissues to form vascularized cardiac organoids;

[0051] Among them, the components in the multiple culture media include LN521.

[0052] The preparation step method is simple, and continuous culture is carried out by adopting multiple culture media, wherein the components in the multiple culture media include LN521. Differentiation is induced by multiple culture media so that the grown cardiac organoids with vascular cavities have a chamber structure similar to that of the heart. The cardiac organoids with vascular cavities can simulate the nutrient supply and metabolite discharge of cardiac tissue, help the metabolism of the heart, and promote the delivery of oxygen. The volume of the cardiac organoids can be increased, and the contractility of the cardiac organoids can be enhanced. The growth and development of the heart can be better simulated, and the maturation of myocardial cells can be better supported. The cardiac organoids prepared by the above preparation steps have an average diameter of about 1 mm, contain myocardial cells, vascular endothelial cells, fibroblasts, endocardium and epicardium, self-organize to form a tubular structure composed of vascular endothelial cells, and can contract rhythmically, so that they can be better used in the study of cardiovascular diseases.

[0053] It should be noted that LN521 in this application can promote the adhesion and expansion of endothelial cells in a three-dimensional environment by binding to integrins on the surface of endothelial cells, and this cell-matrix interaction helps to establish and maintain cell polarity, which is a prerequisite for the formation of vascular lumen.

[0054] Since the formation of vascular lumen depends on the establishment of endothelial cell polarity and the formation of lumen mask, LN521 helps endothelial cells stretch and expand in a specific direction by affecting the polarity proteins of cells, thus forming a lumen-like structure. At the same time, as an important component of the basement membrane, LN521 helps the formation and stability of the basement membrane, thus providing structural support for the formation and maintenance of the vascular lumen.

[0055] It should be noted that the cell culture method in the step is a suspended three-dimensional culture, that is, the 3D cardiac organoid spheres are shaken and cultured (without a feeder layer, only floating in the culture medium and placed in a 37°C, CO2 incubator for culture, with a shaking speed of 40rpm / min to 70rpm / min,

[0056] In some embodiments, the pluripotent stem cells can be commercial embryonic stem cells (ESCs) or human induced pluripotent stem cells (iPSCs). Induced pluripotent stem cells and embryonic stem cells are used because both have pluripotency, high efficiency and scalability. The cardiac organoids generated using these two can more accurately simulate the structure and function of the human heart, thereby providing effectiveness and reliability for these applications.

[0057] In some embodiments, the steps of step S10 include:

[0058] Step 101, providing pluripotent stem cells, mixing the pluripotent stem cell suspension with a cell suspension, incubating overnight, changing the medium, and culturing at 35-37° C. for 24 h to 48 h to form embryoids.

[0059] It should be noted that embryoid bodies (EBs) are three-dimensional cell populations formed by in vitro aggregation of induced pluripotent stem cells (such as embryonic stem cells or induced pluripotent stem cells). It simulates the microenvironment of early embryonic development, in which the self-organization and differentiation process of cells can be observed. This structure is used to study cell differentiation, embryonic development, and disease models. Embryoid bodies can further develop into a variety of in vivo cell types, including heart cells, to help study the formation and function of cardiac organoids.

[0060] Specifically, the operation steps of step 101 include: digesting the stem cells in the logarithmic growth phase and resuspending them in a stem cell culture medium containing ROCKi, wherein the stem cell culture medium is mTeSR Plus culture medium, and ROCKi is Y27632 at a concentration of 5 to 20 μM. The digested stem cell suspension is inoculated into a 96-well cell culture plate with ultra-low adsorption. Add 200 μl of cell suspension to each well, incubate overnight at 37 ° C, change the medium on the second day, and continue to culture at 37 ° C for 24h to 48h to form embryoids. On the third day, shake and culture at 37 ° C and 5% CO2 for 24h at 40rpm / min to 70rpm / min, and then induce differentiation of cardiac organoids.

[0061] In some embodiments, in step S20, any of the multiple culture media includes a basal culture medium and a differentiation inducing factor, and the multiple culture media include a first culture medium (M1), a second culture medium (M2), a third culture medium (M3), a fourth culture medium (M4) and a fifth culture medium (M5), wherein:

[0062] The differentiation inducing factors of the first culture medium include CHI R99021 and sodium tanshinone;

[0063] The differentiation inducing factors of the second culture medium include IWP2, IWP4 and SB431542; and / or,

[0064] The differentiation inducing factors of the third culture medium include IWP2, VEGF-A and LN-521; and / or,

[0065] The differentiation inducing factors of the fourth culture medium include insulin, VEGF-A and LN-521; and / or,

[0066] The differentiation inducing factors of the fifth culture medium include insulin and VEGF-A.

[0067] In this step, multiple culture media are used for continuous culture to induce differentiation to obtain cardiac organoids with vascularization. It should be noted that the main purpose of the first culture medium is to induce mesoderm differentiation, wherein the differentiation induction factor CHI R99021 in the culture medium is a selective inhibitor, and its main function is to inhibit GSK-3β (glycogen synthase kinase 3β), thereby activating the Wnt / β-catenin signaling pathway, which is usually used to promote the differentiation of stem cells into mesoderm or cardiomyocytes, and tanshinone sodium is a traditional Chinese medicine extract and a stable form of tanshinone, which is often used to promote cell growth and differentiation, especially in the study of cardiovascular and nervous systems, it may play a role by regulating intracellular signaling pathways, such as anti-oxidative stress and regulating cell apoptosis, and cooperate with CHI R99021 to promote cardiac mesoderm differentiation; the main purpose of the second culture medium is to induce cardiac progenitor cell differentiation, wherein the differentiation induction factors, such as IWP2 and IWP4, are inhibitors of the Wnt signaling pathway, which regulate the differentiation of stem cells into specific cell lineages by inhibiting the activity of the Wnt signaling pathway. They are often used to block overactive Wnt signaling pathways, thereby guiding cells to differentiate into certain lineages; the role of the third culture medium is to promote endothelial differentiation. Among them, VEGF-A is a vascular endothelial growth factor that mainly promotes angiogenesis. It plays a role in promoting vascularization and related cell lineages during cell differentiation, especially in promoting the differentiation of endothelial cells.

[0068] The laminin LN-521 is a type of extracellular basement membrane (BM) protein, which is a heterotrimer with 5 chains, 4 β chains and 3 γ chains. Laminin LN-521 can support the growth of stem cells and maintain their pluripotency. Laminin LN-521 works together with vascular epidermal growth factor VEGF-A in the process of participating in the induction and differentiation of cardiac organoids to promote the formation of vascular lumen structure in cardiac organoids; the role of the fourth culture medium is to promote the maturation of early cardiomyocytes, among which Insulin is a hormone mainly used to regulate cell metabolism and proliferation. During cell differentiation, it helps to provide growth factor support and promote the maturation of certain cell types; the role of the fifth culture medium is to maintain the growth of vascularized cardiac organoids.

[0069] In some embodiments, wherein the basal medium of the first culture medium comprises 1640 and B27 without insulin; and / or,

[0070] The basal medium of the second culture medium comprises 1640 and B27 without insulin; and / or,

[0071] The basal medium of the third culture medium comprises 1640 and B27 without insulin; and / or,

[0072] The basal medium of the fourth culture medium comprises 1640 and B27 without insulin; and / or,

[0073] The basal medium of the fifth culture medium includes DMEM and palmitic acid.

[0074] Among the above-mentioned multiple culture media, the basal culture media of the first to fourth culture media include 1640 and B27 without insulin, and the basal culture media of the fifth culture media are DMEM and palmitic acid. Among them, 1640 culture medium is generally used to support the growth of various cells, while B27 without insulin is often used for nerve cell culture to help provide growth factors. At the same time, insulin is removed, which is more conducive to improving the efficiency of cardiomyocyte differentiation. DMEM is a common cell culture medium. The palmitic acid (PA) is a long-chain saturated fatty acid containing 16 carbons, which is used to support fatty acid metabolism and cell membrane synthesis. It contributes to the health and survival of cardiomyocytes within a certain range and promotes the maturation of cardiomyocytes.

[0075] In some embodiments, in step S20,

[0076] The differentiation inducing factors of the first culture medium include CHI R99021 and sodium tanshinone, wherein the concentration of CHI R99021 is 3-10 μM, and the concentration of sodium tanshinone is 5-10 ng / mL; and / or,

[0077] The differentiation inducing factors of the second culture medium include IWP2, IWP4 and SB431542, wherein the concentration of IWP2 is 1.25-5 μM, the concentration of IWP4 is 1.25-5 μM, and the concentration of LN-521 is 10-200 ng / mL; and / or,

[0078] The differentiation inducing factors of the third culture medium include IWP2, VEGF-A and LN-521, wherein the concentration of IWP2 is 1.25-5 μM, the concentration of VEGF-A is 5-10 ng / mL and the concentration of LN-521 is 10-200 ng / mL; and / or,

[0079] The differentiation inducing factors of the fourth culture medium include insulin, VEGF-A and LN-521, wherein the concentration of insulin is 5-10 μg / mL, the concentration of VEGF-A is 5-10 ng / mL and the concentration of LN-521 is 10-200 ng / mL; and / or,

[0080] The differentiation inducing factors of the fifth culture medium include insulin and VEGF-A, wherein the concentration of the insulin is 5 to 10 μg / mL and the concentration of the VEGF-A is 5 to 10 ng / mL.

[0081] Culture medium within the above concentration range can optimize the differentiation and maturation of cardiac organoids, ensuring that cells receive appropriate nutrients and signals, thereby improving the structure and functional performance of the organs.

[0082] In some embodiments, the basal culture medium of the fifth culture medium includes DMEM and palmitic acid, and the concentration of the palmitic acid is 20 to 50 μM. Within this range, cells or microorganisms can be ensured to grow in a stable and suitable environment.

[0083] Specifically, Table 1

[0084]

[0085] Specifically, the operation steps of step 20 include: taking the culture medium in Table 1 to induce differentiation of cardiac organoids. Add M1 to the embryoids and culture for 40h to 48h. Discard the supernatant, add 1640 culture medium plus B27(-ins) to the wells, and culture for 20h to 24h; discard the supernatant, add M2 to the wells, and culture for 20h to 24h. Replace with M3 and culture for 20h to 24h. Replace with M4, culture for 40h to 48h, replace with M5, change the liquid once a day, and the cardiac organoids begin to beat on the 7th to 10th day of induction of differentiation, and the cardiac organoids can be used for subsequent identification around the 9th to 10th day.

[0086] The present application also provides a cardiac organoid, which is prepared by the method of self-organizing to form a vascularized cardiac organoid as described in any one of the above items. The structure of the cardiac organoid is closer to a real heart and can be used in the fields of heart development, regenerative medicine and cardiovascular drug screening.

[0087] The cardiac organoids proposed in this application possess all the beneficial effects of the above-mentioned method of self-organizing to form vascularized cardiac organoids, which will not be described in detail here.

[0088] The following are examples of the present application. The examples described below are exemplary and are only used to explain the present application, and should not be construed as limiting the present application. If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially. The culture conditions in the cell culture incubator in the following examples are 37°C, 5% CO2.

[0089] Example 1

[0090] Material:

[0091] Purchase human pluripotent stem cells Xiamen Yimo Biotechnology Co., Ltd.

[0092] Stem cell culture medium was purchased from STEMCELL technologies

[0093] The steps for preparing cardiac organoids are as follows:

[0094] Human pluripotent stem cells were digested, resuspended and plated. Specifically, human hESCH9 cells were cultured in stem cell culture medium. When the cells grew to the logarithmic phase, the supernatant was removed, washed once with DPBS, digested with Accutase at room temperature for 2 minutes, then the digestion solution was aspirated, and resuspended in stem cell culture medium containing 10 μM ROCKi, and inoculated into a 96-well ultra-low adsorption U-shaped plate at 5000 cells / well, centrifuged at 1000 rpm / min for 3 minutes, and then transferred to a 37°C, 5% CO2 incubator for 2 days to form embryoids.

[0095] The cardiac organoids were induced to differentiate. Specifically, the differentiation was induced according to the following steps.

[0096] Step 1: Add M1 basal medium to the embryoids, add 3 μM CHIR99021 and 5 ng / mL sodium tanshinone, and culture for 48 h;

[0097] Step 2: discard the supernatant, add M1 basal medium to the wells, and culture for 24 h;

[0098] Step 3: discard the supernatant, add M2 basal culture medium containing 5 μM IWP2, 2 μM IWP4, and 5 μM SB431542 to the wells, and culture for 24 hours.

[0099] Step 4: discard half of the supernatant, replace the M3 basal medium in the wells, add 5 μM IWP2, 5 ng / mL VEGF-A and 100 ng / mL laminin LN-521, and culture for 24 hours.

[0100] Step 5, add M4 basal culture medium, 10 μg / mL insulin, 5 ng / mL VEGF-A and 100 ng / mL laminin LN-521 to the wells and culture for 48 hours.

[0101] Step 6: Add M5 low-glucose basal medium, 10 μg / mL insulin, and 5 ng / mL VEGF-A to the wells, and change the medium once a day.

[0102] Cardiac organoids begin to beat on the 7th to 10th day of induction of differentiation, and can be used for subsequent identification around the 9th to 10th day.

[0103] Comparative Example 1

[0104] Differentiation of cardiac organoids using medium without LN-521

[0105] Comparative culture medium composition: LN-521 was not added to differentiation medium M3 and M4, and the rest was similar to Example 1.

[0106] Performance Testing

[0107] Cardiac organoid structure and function testing

[0108] 1. Monitoring the Growth of Cardiac Organoids

[0109] The process of changes of induced cardiac organoids obtained in Example 1 over time is as follows Figure 1 As shown in the figure, on the 3rd day, the organoids increased significantly, on the 5th and 6th days, the organoids became dense and their light transmittance decreased, on the 7th day, there was a weak pulsation of the myocardium, and on the 8th day, the heart organoids began to beat obviously. Figure 2 As shown, Figure 2 Figure a is a bright field image (40×) of the cardiac organoid of comparative example 1 grown on the 10th day. The edges of the organoid spheres are messy and the light transmittance of the spheres is poor. Figure 2 b is a bright field image (40×) of the cardiac organoid obtained in Example 1. The boundaries of the organoid spheres are clear, and the volume of the cardiac organoid in Example 1 is larger than that of the cardiac organoid in Comparative Example 1.

[0110] 2. Fluorescence staining of cardiac organoid slices

[0111] The cardiac organoids obtained in Example 1 were sliced ​​and fluorescently stained for the vascular endothelial cell marker CD31. The results are as follows: Figure 3 and Figure 4 As shown, Figure 3 -LN521 in the example is comparative example 1, and +LN521 in the example is embodiment 1. Compared with comparative example 1, Figure 3 The CD31+ magnified image on the right shows that the internal self-organization of the cardiac organoid obtained in Example 1 produced a vascular lumen-like structure. Figure 4 It can be seen that the percentage of the ratio of the annular blood vessel area to the CD31+ area formed in Example 1 is higher than that in Comparative Example 1, indicating that the addition of LN521 in the present invention can promote the formation of tubular structures of vascular endothelial cells, and the annular blood vessel area and CD31+ area formed in Example 1 are also higher than those in Comparative Example 1, indicating that the addition of LN-521 in the present invention also promotes VEGF-A-induced vascular endothelial cell differentiation.

[0112] 3. Whole-body fluorescent staining of cardiac organoids

[0113] The cardiac organoids obtained on the 10th day of differentiation from the cardiac organoids obtained in Example 1 were fluorescently stained using the cardiomyocyte-specific marker cTn I, the endocardial marker NFAT2, the epicardial marker WT1, the fibroblast marker VIM and the cell nucleus DAPI. Figure 5 As shown, Figure 5 The upper row of pictures represents the presence of endocardial and epicardial cells in the cardiac organoids obtained in Example 1, and the lower row of pictures represents the presence of fibroblasts and vascular endothelial cells in the cardiac organoids obtained in Example 1, which indicates that the interior of the cardiac organoids obtained in Example 1 contains cardiomyocytes, epicardium, endocardium, fibroblasts and vascular endothelial cells.

[0114] Analysis of cardiomyocyte sarcomeres in cardiac organoids

[0115] The myocardial cell sarcomeres in the cardiac organoids obtained in Example 1 were analyzed. Figure 6 As shown, Figure 6 -LN521 is Comparative Example 1, +LN521 is Example 1. Compared with the cardiomyocytes in Comparative Example 1, there is no significant difference in the sarcomere length of the cardiomyocytes of the cardiac organoids in Example 1. This indicates that the addition of LN-521 has no significant effect on the sarcomere formation of cardiomyocytes. The results of the lactate dehydrogenase (LDH) activity test in cardiac organoids show that the release of lactate dehydrogenase (LDH) in the cardiac organoids in Example 1 is lower than that in the cardiac organoids in Comparative Example 1, indicating that the vascularized lumen formed by the cardiac organoids obtained in the present invention may be more conducive to the nutrient supply and metabolite discharge of the cardiac organoids compared with Comparative Example 1, and the degree of tissue damage is lower, so that the activity of the obtained cardiac organoids is higher.

[0116] 6. Cardiac organoid contractile function testing

[0117] The cardiac organoids obtained on the 10th day of differentiation in Example 1 and Comparative Example 1 were recorded with a 10-second video at 60-90 frames per second, and then the beating frequency, contraction amplitude and contraction time 50 (APD50) of the cardiac organoids were analyzed using Image J software. Figure 7 The data shows that, Figure 7 -LN521 is Comparative Example 1, and +LN521 is Example 1. The contraction frequency of the cardiac organoids in Example 1 and Comparative Example 1 is about 1 second / time, and compared with Comparative Example 1, the contraction amplitude of the cardiac organoids in Example 1 is larger and the cardiac contractile force function is stronger.

[0118] VII. Cardiac organoid electrical conduction function testing

[0119] The cardiac organoids obtained on the 10th day of differentiation in Example 1 and Comparative Example 1 were stained with calcium ion-specific fluorescein-4, and calcium transient (CaT) signals were imaged in real time. Figure 8 Display, among which, Figure 8 -LN521 is comparative example 1, and +LN521 is example 1. Compared with comparative example 1, typical myocardial cell calcium waves appeared in the cardiac organoids obtained in example 1, and the peak value of calcium ion signal in the myocardial cells was higher. Even though there was no significant difference in CaT50, CaT80 in example 1 was significantly reduced, further confirming that the cardiac organoids obtained in the present invention have greater contractility, the obtained myocardial cells are more mature, and have perfect electrical conduction function.

[0120] The above are only preferred embodiments of the present application, and do not limit the scope of the present application. For those skilled in the art, the present application may have various changes and modifications. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the scope of the patent protection of the present application.

Claims

1. A method for self-organizing to form vascularized cardiac organoids, characterized in that: The following steps are involved: S10, providing pluripotent stem cells, and culturing the pluripotent stem cells in suspension to form embryoid bodies; S20, continuously culturing the embryoid bodies using a variety of culture media to induce differentiation and self-organize to form vascularized cardiac organoids; Among them, the components in the multiple culture media include LN521.

2. The method for self-organization of vascularized cardiac organoids according to claim 1, characterized in that: The pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells.

3. The method for self-organization of vascularized cardiac organoids according to claim 1, characterized in that: The steps of step S10 include: Step 101, providing pluripotent stem cells, mixing the pluripotent stem cell suspension with a cell suspension, incubating overnight, changing the medium, and culturing at 35-37° C. for 24 h to 48 h to form embryoids.

4. The method for self-organization of vascularized cardiac organoids according to claim 1, characterized in that: In step S20, any one of the multiple culture media includes a basal culture medium and differentiation inducing factors, and the multiple culture media include a first culture medium, a second culture medium, a third culture medium, a fourth culture medium and a fifth culture medium, wherein: The differentiation inducing factors of the first culture medium include CHIR99021 and sodium tanshinone; and / or, The differentiation inducing factors of the second culture medium include IWP2, IWP4 and SB431542; and / or, The differentiation inducing factors of the third culture medium include IWP2, VEGF-A and LN-521; and / or, The differentiation inducing factors of the fourth culture medium include insulin, VEGF-A and LN-521; and / or, The differentiation inducing factors of the fifth culture medium include insulin and VEGF-A.

5. The method for self-organization of vascularized cardiac organoids according to claim 4, characterized in that: in, The basal medium of the first culture medium comprises 1640 and B27 without insulin; and / or, The basal medium of the second culture medium comprises 1640 and B27 without insulin; and / or, The basal medium of the third culture medium comprises 1640 and B27 without insulin; and / or, The basal medium of the fourth culture medium comprises 1640 and B27 without insulin; and / or, The basal medium of the fifth culture medium includes DMEM and palmitic acid.

6. The method for self-organization of vascularized cardiac organoids according to claim 4, characterized in that: In step S20, The differentiation inducing factors of the first culture medium include CHIR99021 and sodium tanshinone, wherein the concentration of CHIR99021 is 3-10 μM, and the concentration of sodium tanshinone is 5-10 ng / mL; and / or, The differentiation inducing factors of the second culture medium include IWP2, IWP4 and SB431542, wherein the concentration of IWP2 is 1.25-5 μM, the concentration of IWP4 is 1.25-5 μM, and the concentration of LN-521 is 10-200 ng / mL; and / or, The differentiation inducing factors of the third culture medium include IWP2, VEGF-A and LN-521, wherein the concentration of IWP2 is 1.25-5 μM, the concentration of VEGF-A is 5-10 ng / mL and the concentration of LN-521 is 10-200 ng / mL; and / or, The differentiation inducing factors of the fourth culture medium include insulin, VEGF-A and LN-521, wherein the concentration of insulin is 5-10 μg / mL, the concentration of VEGF-A is 5-10 ng / mL and the concentration of LN-521 is 10-200 ng / mL; and / or, The differentiation inducing factors of the fifth culture medium include insulin and VEGF-A, wherein the concentration of the insulin is 5 to 10 μg / mL and the concentration of the VEGF-A is 5 to 10 ng / mL.

7. The method for self-organization of vascularized cardiac organoids according to claim 5, characterized in that: The basal culture medium of the fifth culture medium includes DMEM and palmitic acid, and the concentration of the palmitic acid is 20 to 50 μM.

8. A cardiac organoid, characterized in that: The cardiac organoid is prepared according to the method for self-organization to form vascularized cardiac organoids as described in any one of claims 1 to 7.

Citation Information

Cited By

  • Heart organoid and in-vitro preparation method thereof

    CN119570719A